Genotypic-resistance assays and anti-retroviral therapy

Lancet

Volumn 349, Issue 9064, 1997, Pages 1489-1490

  Deeks, S G ^a   Abrams, D I ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

DRUG RESISTANCE; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; VIRUS GENOME; VIRUS PARTICLE; VIRUS REPLICATION;

EID: 0031000440     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)62092-2     Document Type: Note

References (6)

1. JM Coffin HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy Science 267 1995 483 489
2. MJ Kozal N Shah N Shen Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays Nat Med 2 1996 753 759
3. AJ Japour S Welles RT D'Aquila Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment J Infect Dis 171 1995 1172 1179
4. BA Larder SD Kemp PR Harrigan Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy Science 269 1995 696 699
5. H Jacobsen M Hanggi M Ott In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics and frequencies J Infect Dis 173 1996 1379 1397
6. JH Condra WA Schleif OM Blahy In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors Nature 374 1995 569 571